The acquisition takes the combined number of sites in the Linnaeus Group to 57.
Brendan Robinson, Village Vet director, said: "When looking for investment, there were a number of options open to us, however, we wanted to ensure we partnered with a group which had the same ethos and ethics as ourselves, who are dedicated to providing an excellent all-round service.
"Having chosen Linnaeus, we look forward to the partnership providing great opportunities for collaborating in CPD, sharing best practice, forming relationships with Specialists and other teams within the group, as well as being part of a bigger family."
Lynne Hill, chief executive of the Linnaeus Group (pictured right), said: "Both Village Vet and its referral centre, London Vet Specialists, will be very welcome additions to the Linnaeus team and complement our existing practices, especially those located in the South East.
"All three existing Village Vet directors will be continuing with the practice and remain committed to its success, working alongside the Linnaeus Group."
For more information about the Linnaeus Group, visit www.linnaeusgroup.co.uk.
There are an estimated 100,000 Persian cats in the UK, popular for their luxurious coat and flattened face. However, many of the health issues identified in the study, including haircoat disorders, dental disease, overgrown nails and eye discharge, may be related to precisely the qualities which have made the breed popular.
The researchers say that the results of the new study will help breeders to select which cats to breed from, veterinary surgeons to spot diseases earlier and owners to ensure that they take preventive measures for common conditions in the breed. They will also help the public understand more about the welfare challenges relating to owning and caring for Persian cats.
By analysing the clinical records of 3,325 Persian cats using the RVC’s VetCompass programme, the researcher found:
64.9% of Persian cats had at least one disorder recorded.
The most common specific disorders were haircoat disorder (12.7%), dental disease (11.3%), overgrown nails (7.2%) and eye discharge (5.8%).
Dental disease was more common in males, while claw/nail problems were more common in females.
The most common causes of death were kidney disease (23.4%) and cancer (8.5%).
The average adult bodyweight of a Persian cat was 3.9 kg.
Male Persian cats (average 4.3kg,) were heavier than females (average 3.4 kg).
The average lifespan of a Persian cat is 13.5 years.
Dr Dan O’Neill, lead author and VetCompass veterinary epidemiologist at the RVC, said: "Welfare concerns over brachycephaly [flat faces) in dogs have been recognised for some years.
"Now, our new study of Persians provides evidence that cats with flattened faces are similarly predisposed to some unpleasant and debilitating conditions.
"Hopefully this evidence baseline will kick-start demands to reform the Persian breed’s health by breeding towards a less extreme body shape. Additionally, owners of Persians need to be especially alert to dental, eye and haircoat issues in their cats and seek treatment at the earliest signs of ill-health."
Danièlle Gunn-Moore, Professor of Feline Medicine, University of Edinburgh and co-author said: "Along with growing health and welfare concerns for brachycephalic dogs, our studies raise the same concerns for brachycephalic cats. It is essential we recognise that brachycephalic cats have many of the same problems as brachycephalic dogs, with the most severely brachycephalic individuals having the most serious health problems. We need to start breeding away from extreme brachycephalia before we cause even more harm to these gracious creatures."
Reference
Photo: Danièlle Gunn-Moore
Suprelorin 4.7mg is a sustained release implant containing deslorelin (a GnRH super agonist) which has been EMA and VMD approved for use in male cats from 3 months of age.
The implant provides temporary infertility and suppression of urine odour and of sexual behaviours such as libido, vocalisation, urine marking, and aggressiveness in intact male cats.
The implant typically lasts for at least 12 months1.
Virbac says that in most cats, testosterone levels drop within 2 weeks after implantation, followed by reduced testicular volume and reduced size of penile spines from weeks 4-8 after implantation.
Sexual behaviours begin to decrease within a week after treatment, starting with reduced vocalisation, followed by reduction in libido, urine odour, urine marking, and aggressiveness from 4 weeks after implantation.
Induction of infertility is achieved from approximately 6 weeks.
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "The ability to use Suprelorin in male cats provides an opportunity for practices to offer a choice when it comes to neutering, and to tailor their recommendations to meet the individual needs of both the cat and the client.
"Suprelorin provides an ideal solution for cats where the client wants the benefit of surgery without the permanent loss of fertility, where there is an anaesthetic risk in high value kittens or where there is benefit to allow enough time between neutering, vaccination and homing to minimise stress".
The implant is inserted subcutaneously, under the loose skin on the back between the lower neck and the lumbar area.
Virbac says implantation is a quick procedure and does not require anaesthesia or hospitalisation, which can be of particular benefit in practices facing pressures on surgical waiting lists.
Suprelorin 4.7mg has also received a licensed claim in pre-pubertal female dogs for the induction of temporary infertility to delay the first oestrus and heat signs, and to prevent pregnancy at a young age in intact and healthy sexually immature female dogs.
The implant should be administered between 12 and 16 weeks of age.
For more information, talk to your Virbac Territory Manager or the Virbac Technical Team on 01359 243243.
It might explain why, according to the research, around 14% of British adults actively encourage fox visitors into their garden, with 10% of adults leaving out food, water or toys for foxes and 48% of them admitting they would feel disappointed if their garden fox did not return at night.
Bayer highlights research which showed an increase in the number of foxes infected with Angiostrongylus, from 7.3% in 2008 to 18.3% in 20152,3.
More recent work led by the aptly named Professor Mark Fox at the Royal Veterinary College has shown that, in the Greater London area, nearly three out of four foxes (74.4%) are infected with the parasite.4
Mark said: "We had previously mapped the distribution of Angiostrongylus in pet dogs by seeing how many cases every small animal practice in Britain had seen over the previous 12 months. This revealed the parasite’s widespread distribution coupled with hotspots of infection in Greater London/south-east England and South Wales, where dogs were four to five times more likely to be infected than elsewhere in the country.
"We then investigated why hot spots were seen in these locations and, apart from land type, dog density and climatic factors, we found that the mere presence of foxes locally increased the risk of infection in dogs five-fold."
"The overall prevalence of infection in Greater London was very high, at just under 75 per cent4, and prevalence was maintained at this level throughout the year. These results suggest that foxes act as year-round, wild animal reservoirs of infection for urban dogs."
Donna Tomlinson, Bayer Senior Brand Manager said: "The recent ‘pet foxes’ pet owner research results coupled with the lungworm prevalence fox studies highlights the growing concern of the spread of Angiostrongylus vasorum in the UK and the need for adequate preventative measures for pet dogs.
"Veterinary professionals are perfectly placed to advise dog owners on the risk of their pets becoming infected with the parasite, including the growing role of foxes as potential wild animal reservoirs of Angiostrongylus, as well as advising pet owners to use a monthly spot-on prevention such as Advocate.
"Treatment with products containing moxidectin, such as Advocate, not only kills lungworms present at the time of treatment but also kills larvae after ingestion preventing new infections. Regular monthly use prevents disease and ensures that no lungworm larvae are shed in dogs’ faeces which helps to prevent the spread of the parasite in the environment."
To highlight the increased prevalence of lungworm in foxes Bayer has created a poster for veterinary practices, which you can get from the Bayer Vet Centre at: https://www.vetcentre.bayer.co.uk/marketing-and-resources/advocate-fox-poster
References
Locum David John Porter has been struck off by the RCVS Disciplinary Committee for rude and aggressive behaviour, deficient clinical standards and obstructing the Committee's investigation into the complaints against him.
Three charges were found against Mr Porter.
The first charge (charge A) concerned failure to communicate courteously and respectfully with colleagues. This charge related to four incidents as follows:
In finding him guilty of this charge the Committee referred to his “wholly unacceptable exchanges with other veterinary surgeons and veterinary nurses and ancillary practice staff members with whom he was working on the dates in question.”
The second charge for which he was found guilty (charge C) concerned what the Committee called “his seriously deficient clinical standards when treating animals under his care”, in particular that:
Within charge C he was cleared of two further parts of the charge – first, that he failed to discuss euthanasia with a client in relation to a kitten and failed to provide the client with sufficient advice and instructions regarding after-care; and, second, that he prescribed steroids to treat a kitten for muscle strain at a time when it was recovering from surgery.
The third charge for which he was found guilty (charge D) relates to Mr Porter’s failure, between 7 February 2013 and 31 October 2014, to respond adequately to communications from the RCVS. In particular that:
As to the conduct found proved in relation to charge D, the Committee set out its findings of fact and declared: “What Mr Porter chose to do was to attempt to obstruct the College in its attempts to investigate the complaints laid against him and, thereafter, its attempts to bring him before the Committee to answer the charges preferred against him. In short, he has directly questioned, and then disregarded and thwarted, the legitimate role of his professional regulatory body.”
The Committee’s reasons for taking a serious view of such conduct were expressed in the following words: “Both the public and other members of the profession must be entitled to rely on the expectation that all veterinary surgeons, as responsible professional persons, will co-operate fully and promptly to all proper enquiries made of them by the College. This is the wider public interest factor which means that deliberate attempts to thwart the College’s enquiries into complaints must, in our judgment, come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect.”
During the course of the hearing, which began in June 2015 and was adjourned three times, Mr Porter was cleared of charge B against him which concerned alleged refusal to undertake out-of-hours work for the Clent Hills Veterinary Group having previously indicated he would undertake such work.
In making the decision on the sanction in this case, Judith Webb, chairing the Disciplinary Committee and speaking on its behalf, said: “In reaching our conclusion as to the sanction which is merited in this case we have taken into account the totality of Mr Porter’s conduct and failings. We consider that the conduct pertaining to Charges D(i) and (ii), even when viewed separately, demand the imposition of a direction for the removal of Mr Porter’s name from the Register.
“When that conduct is considered in conjunction with the other misconduct found proved in relation to Charges C1 to C4, which identify his clinical failings, and Charges A1 to A4, which demonstrate unprofessional behaviour in the workplace, we unhesitatingly conclude that there is no other sanction that could be considered sufficient, other than that of erasure.”
Simparica Trio contains sarolaner, which is active against fleas and ticks; moxidectin, effective against heartworm, lungworm and some intestinal worms; and pyrantel embonate, effective against gastrointestinal nematodes (hookworms and roundworms).
Dr. Domenico Otranto1, DVM, PhD, DipEVPC, Professor in Veterinary Parasitology at the University of Bari (Italy), said: "The approval of Simparica Trio provides veterinarians a safe and effective option for the treatment of mixed external and internal parasitic infestations in dogs in the form of a new oral chewable.
"Simparica Trio has been shown to rapidly kill fleas and ticks with concurrent efficacy for the prevention of heartworm disease and angiostrongylosis (lungworm disease) and treatment of intestinal round- and hookworms. The convenience of a once monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection."
Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, said: "We are excited to bring Simparica Trio to veterinarians in the European Union as a new, effective triple combination parasiticide for dogs."
MiPet Cover has been developed using feedback from CVS's own veterinary surgeons and veterinary team members who deal with insurance claims on a daily basis.
The company says it'll offer a new level of transparency to owners, including policy documents which are clear, concise and free of 'legalese'.
As the first insurance range to be integrated directly into a practice management system, it also offers benefits to the veterinary team by speeding up the time taken to provide quotes and to introduce and activate policies.
CVS says the addition of insurance to its range of services is in line with its vision of offering clients complete care for their pets and at this stage, it is focused on offering the new policies to clients of its existing 420 practices.
VetSurgeon.org spoke to Simon Morrall, the insurance professional brought in by CVS to develop the new range of insurance products for the company. He said: "As the UK’s largest provider of veterinary services, we knew that some owners experienced frustrations with insurance and we challenged ourselves to eliminate these problems with the development of MiPet Cover.
"The more research we did, the more we realised that there was an opportunity for us to go one better and to draw on the extensive experience of our veterinary teams to produce an insurance solution built on transparency, choice and efficiency, which would give our clients access to the very best treatment when they needed it.
"With the launch of MiPet Cover, I believe that’s what we’ve done. It has been received positively by our teams across the country and we are excited about the potential it has to help both our clients and our veterinary teams."
A single 0.5ml vaccination provides 12 months immunity against all three pathogens, which will make vaccination more convenient and should help improve levels of compliance against variant strains of RHD which is currently estimated to be at around only 60% of the vaccinated rabbit population.
Nobivac Myxo-RHD Plus is available in a pack of five, single dose vials, with a shelf-life of two years. The vaccine can be used from the age of five or seven weeks onwards to achieve the full duration of immunity. Immunity is provided within three weeks of administration.
Leonora Bell, Product Manager at MSD Animal Health said: "It's clear that this year the usually busy spring season, where purchasing and vaccinating rabbits is at its highest, will not be as predictable as previous years. Vaccinating rabbits is unlikely to be at the top of your agenda. MSD Animal Health's new Nobivac Myxo-RHD PLUS has arrived, however, so this is a good opportunity to understand how to safely switch vaccinated rabbits and introduce new rabbits to vaccination. This is a time when clients can be encouraged back into your practice, ideally prior to the increase in infectious disease which we tend to see during the peak summer months.
"The variant RHD-2 strain appears now to predominate in cases of rabbit haemorrhagic disease and readily transfers over long distances via flies and the wind. Vaccinating rabbits that live both outdoors and indoors is therefore vital. Rabbits are popular pets and rabbit owners are highly motivated to seek veterinary advice once they are made aware of their pet's specific health needs. They are, however, much less likely to take their pet to a veterinary practice than cat or dog owners or to seek advice on vaccination, neutering or other routine health matters."
Leonora added: "Production of our existing Nobivac Myxo-RHD vaccine will necessarily be replaced with the new Nobivac Myxo-RHD PLUS to ensure that rabbits are vaccinated in the most appropriate way. Following the correct switching protocol is therefore vital. For unvaccinated rabbits it's a simple case of starting with the new vaccine. For rabbits due for a booster of Myxomatosis, RHD1 and RHD2, again, vets can simply switch to the new vaccine when the booster is normally due. Where rabbits have already only been vaccinated with the existing Nobivac Myxo-RHD vaccine it is recommended that vets vaccinate the rabbit with an inactivated RHD-2 vaccine, such as Filavac or Eravac vaccine, as soon as possible. For boosters due later this year and all subsequent boosters, use Nobivac Myxo-RHD PLUS."
The launch of the vaccine is being supported by a range of educational materials designed to help vets switch and encourage new rabbit owners into the practice. A new website is also in the pipeline, with rabbit owner support videos, an educational launch webinar, a detailer, practice posters, noticeboard materials and e-mail templates as vaccination reminders for rabbit owners.
For further information contact your MSD Animal Health account manager or visit www.nobivacmyxorhdplus.co.uk.
You could otherwise call them "Britain's Best Places to Get Ill (if you are a dog)", or alternatively "Britain's Worst Places to Open (another) Veterinary Practice".
The best town, in the whole of the UK, for a dog to get ill, is, wait for it ... Worcester, which has a veterinary practice for every 7,308 people. Not far behind, Worthing, Chelmsford, Southampton, and Exeter all have a practice for every 9,916 people or less.
At the other end of the scale, the very worst place for a dog to get ill - and possibly the best place to open a practice - is Birmingham, where (according to this research) each practice serves 227,424 people. London was in second place (one practice for every 210,119 people), Manchester in third (1:181,833) and St Helens in fourth (1:179,331).
The research was part of a bigger analysis to see where in the country pets are best catered for, according to the number of pet shops, dog groomers, vets, parks, dog walkers and kennels in the area, as listed on yelp.co.uk.
Blackpool was the clear winner, with pet-friendly facilities for every 2,680 people. In fact, it was the only Northern town in the top ten. In second was Chelmsford and in third was Woking.
The full rankings of UK towns and cities by number of veterinary practices per capita was:
1. Worcester (.0001368)2. Worthing (.0001277)3. Chelmsford (.0001192)4. Southampton (.0001189)5. Exeter (.0001008)6. Cheltenham (.0000939)7. Gloucester (.0000930)8. Eastbourne (.0000872)9. Watford (.0000828)10. Cambridge (.0000801)11. Oxford (.0000776)12. Bath (.0000742)13. Maidstone (.0000715)14. Woking (.0000692)15. Reading (.0000675)16. Southend-on-Sea (.0000660)17. Ipswich (.0000650)18. Blackpool (.0000643)19. Norwich (.0000641)20. Swindon (.0000635)21. Crawley (.0000627)22. York (.0000625)23. Blackburn (.0000605)24. Telford (.0000569)25. Brighton (.0000555)26. Poole (.0000529)27. Newport (.0000528)28. Bournemouth (.0000513)29. Lincoln (.0000508)30. Peterborough (.0000503)31. Dundee (.0000471)32. Solihull (.0000467)33. Portsmouth (.0000466)34. Wolverhampton (.0000462)35. Rochdale (.0000458)36. Northampton (.0000443)37. Belfast (.0000441)38. Newcastle upon Tyne (.0000439)39. Bristol (.0000435)40. Basildon (.0000434)41. Warrington (.0000429)42. Nottingham (.0000425)43. Kingston upon Hull (.0000422)44. Luton (.0000419)45. Coventry (.0000416)46. Cardiff (.0000414)47. Slough (.0000403)48. Edinburgh (.0000390)49. Derby (.0000389)50. Oldham (.0000385)51. Plymouth (.0000380)52. Colchester (.0000368)53. Middlesborough (.0000356)54. Bolton (.0000351)55. Gateshead (.0000346)56. Basingstoke (.0000342)57. Glasgow (.0000338)58. Stoke-on-Trent (.0000313)59. Stockport (.0000275)60. Milton Keynes (.0000262)61. Doncaster (.0000259)62. Wigan (.0000246)63. Swansea (.0000244)64. Liverpool (.0000224)65. Aberdeen (.0000219)66. Wakefield (.0000205)67. Sheffield (.0000190)68. Sunderland (.0000180)69. Rotherham (.0000152)70. Leicester (.0000141)71. Salford (.0000119)72. Bradford (.0000112)73. Leeds (.0000102)74. St Helens (.0000056)75. Manchester (.0000055)76. London (.0000048)77. Birmingham (.0000044)
Boehringer says Senvelgo controls blood sugar levels usually within a week1,2 without the risk of symptomatic hypoglycaemia and without the need for twice daily insulin injections.
Studies have shown that around 1 in 200 cats develop diabetes4,5 - somewhere around 55,000 in the UK - of which 20% are euthanased within a year: 10% because of owners not wanting to inject with insulin, and a further 10% because of lack of success or compliance with insulin.3
This new treatment, with its once-daily oral treatment regime and simple dosing according to bodyweight, could have a significant impact on those numbers.
On top of which, there's no need for glucose curves to determine dosage, it's easily stored and doesn't need refrigeration, and it creates less waste than insulin (1 reusable oral syringe vs 180 insulin syringes).
Samantha Taylor BVetMed(Hons) CertSAM DipECVIM-CA MANZCVS FRCVS said: "This is the development in diabetes management we have been waiting many years for; a practical oral therapy to treat this challenging disease.”
To support vet professionals with using Senvelgo, Boehringer has produced a toolkit that includes a veterinary management guide, CPD webinar, cat owner leaflet and homecare journal, along with websites for vets and cat owners.
www.senvelgo.co.uk
The paper, ‘Mortality Related to General Anaesthesia and Sedation in Dogs under UK Primary Veterinary Care’, published in Veterinary Anaesthesia and Analgesia1, used data from more than 150,000 dogs attending first opinion veterinary practices around the UK.
The study examined the overall risk of death for each dog which had at least one sedation and/or anaesthesia procedure over a set period of time.
The study also looked at anaesthesia related to neutering (spaying and castration) in dogs because these procedures are so common in the UK and anaesthetic risk can be a significant worry for owners.
The findings showed that currently there are 14 deaths in 10,000 dogs within two weeks of sedation/anaesthesia procedures carried out for any reason, of which 10 deaths per 10,000 are within 48 hours of these procedures.
For neutering surgeries in dogs, the risk is even smaller, with one death in 10,000 neuter procedures related to sedation and/or anaesthesia.
No association was seen between the age of puppies at the time of neutering and risk of death.
Factors associated with increased risk of sedation and anaesthetic-related death in this study included:
Certain breeds, such as Cocker Spaniels, were found to be at lower risk compared with mixed breeds.
The team also investigated whether flat-faced ‘brachycephalic’ breeds were associated with higher risk.
Surprisingly, longer-nosed ‘dolichocephalic’ breeds showed four times the odds of sedative/anaesthetic-related death compared with medium-length nose dogs, whereas no additional risk was seen in flat-faced breeds.
The authors of the paper say that overall, these results should provide some reassurance for the veterinary and dog-owning communities regarding the safety of neutering for young puppies, as well as the relative safety of sedatives and anaesthetics for more complex procedures.
For older dogs, those with poorer health or undergoing planned complex surgeries, the results emphasise the value of careful planning to manage the anaesthetic risks.
Urgent procedures, regardless of complexity, were shown to carry greater risk and therefore should be approached with high vigilance and caution.
Dr Dan O’Neill, Associate Professor in Companion Animal Epidemiology at the RVC and co-author of the paper, said:
“This new VetCompass study can help owners deal with these fears by understanding the real anaesthetic risk is not that high: 14 deaths in every 10,000 dogs. Decision-making based on the known can now replace fear of the unknown.”
Full paper: https://doi.org/10.1016/j.vaa.2022.03.006 / https://www.sciencedirect.com/science/article/pii/S1467298722001015
Devon vet Jo Dyer has launched a petition for the RCVS to remove mandatory house visits from the Code of Professional Conduct, in response to the College's call for evidence on the provision of 24-hour emergency veterinary cover.
Clause 3.13 of the Code currently says: "Clients may request attendance on a sick or injured animal away from the practice premises and, in some circumstances, it may be desirable to do so. On rare occasions, it may be necessary on clinical or welfare grounds. The decision to attend away from the practice is for the veterinary surgeon, having carefully balanced the needs of the animal against the safety implications of making the visit; a veterinary surgeon is not expected to risk 'life or limb', or that of anyone else to provide the service."
In other words, whilst it is not mandatory to accede to every request for a home visit, the Code starts by saying: 'it may be desirable' and 'it may be necessary', thereby implying that the veterinary surgeon will need to explain themselves if they decide against.
Jo argues that this ambiguity, coupled with outcome of recent disciplinary cases and the risk, however small, of losing one's livelihood, means that there are many practitioners, particularly younger and less experienced graduates, who are now fearful of refusing home visits, rendering them to all intents and purposes mandatory. It's a situation compounded by the perception that if push comes to shove, a practitioner's actions will be judged by a Disciplinary Committee whose members may be out of touch with the sometimes harsher realities of life in practice.
Jo also points to the increased risk of assault that practitioners face when making home visits, rather than treating the patient from the relative security of the practice premises. She also makes the point that leaving a practice unattended (as can happen if the only vet on the premises has to go on a home visit), may compromise the welfare of any other animals that need emergency treatment in the meantime.
The petition calls for the complete removal of clause 3.13 from the Code, and for clause 3.2 to be amended to read: 'The responsibility for the welfare of an animal rests primarily with the owner, keeper or carer of the animal. Veterinary surgeons are unable to make a definitive decision regarding diagnosis and treatment until they have undertaken a physical examination of an animal. This examination may take place at the surgery or other address entirely at the discretion of the veterinary surgeon on duty. It is expected that farm animals and equines will mainly be examined away from the surgery and pets at the surgery."
Jo said: "It is important to stress that I am not calling for the abolition of home visits, and nor do I think this would be the effect of my proposed change to the CoPC. The profession is almost entirely made up of people who care desperately about the quality of the service they offer, and who want to offer the best to their patients and their clients. Of course we'll continue to make home visits. But I do feel passionately that the decision in each case must rest unambiguously with the veterinary surgeon concerned and not be subject afterwards to the judgement of others."
To sign the petition, visit: http://www.change.org/en-GB/petitions/royal-college-of-veterinary-surgeons-remove-mandatory-house-visits-from-the-code-of-professional-conduct
107 dogs completed the randomised, double-blinded, placebo-controlled clinical trial, which concluded that: "Treatment with anti‐diarrheal probiotic pastes (ADPP) compared to placebo in dogs with acute, uncomplicated diarrhea led to a decrease in the duration of diarrhea and a decrease in the requirement for additional medical intervention because of non‐improvement or deterioration."
Sophie Nixon, Veterinary Research Manager at Protexin Veterinary said: "Dogs with acute diarrhoea are presented to veterinarians on a daily basis yet the evidence base on which to identify appropriate treatment for these cases has been lacking."
James Kyffin, Veterinary Director at Protexin Veterinary said: "We are delighted to have published such a strong clinical study in one of the most well-respected veterinary journals, the Journal of Veterinary Internal Medicine (JVIM).
"At ADM Protexin, we believe it is important to have products that are supported by published studies and the Pro-Kolin Advanced study represents one of the first of its kind looking at the benefit of a probiotic paste in dogs with acute diarrhoea.
"We hope this study will provide vets with the evidence they need to prescribe Pro-Kolin Advanced for their cases and give them the confidence not to dispense other medical management, like antibiotics, that may not be necessary."
The study can be viewed by following the link: https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.15481
The company makes personalised, calorie-controlled fresh meals for dogs; 20 million of them since it launched in 2016.
Each recipe is made of human-grade ingredients and contains 60% single-source protein and 40% vegetables and lentils, with added minerals. There are no preservatives, derivatives or byproducts. Recipes such as "Chow Down Chicken," "Gobble Gobble Turkey," and "Swish Fish Dish" contain less than 5% fat content.
The meals are portioned specifically to each dog according to their calorific need. They are then delivered directly to the customer's door (free-of-charge) via a subscription model.
The model has proven so successful that Butternut Box has recently secured £20m in venture capital to grow the business.
The company launched a referral programme in early May, in which over 50 veterinary surgeons and nurses have signed up to become Butternut Box 'ambassadors'.
Each ambassador is give a unique discount web address which they can give to any client that would benefit from a freshly cooked, calorie-controlled diet for their dog.
If the client redeems the code, a one-time referral fee is credited to the ambassador's account, which can be transferred to a personal account, donated to charity or spent on Butternut Box food for their own use.
Kyle Kennedy from Butternut Box said: "We take great pride in the quality of our food. We think dogs deserve better, and we want to give pet professionals a food they can be proud to recommend."
For more information about being a Butternut Box ambassador, email: kyle@butternutbox.com.
SRD remains a significant problem for the swine industry1. Associated production losses include 30-70% morbidity, a mortality rate of 4-6% (and even higher in severely affected units), decreased feed efficiency and reduced growth rates2.
Zactran contains gamithromycin. Merial says this bactericidal azalide rapidly accumulates in target lung tissue in less than 30 minutes, where it reaches and exceeds the MBC* for SRD pathogens for an extended period, helping to relieve clinical signs and minimise lung damage.
Zactran has a dose rate of 1ml per 25kg in pigs, administered by intramuscular injection.
The product is available in three pack sizes: 50ml glass bottle and 100ml and 250ml polypropylene shock-resistant bottles, and has a 3 year shelf-life.
*MBC: Minimum Bactericidal Concentrations. MBC is the lowest concentration of drug which reduces bacterial counts by 99.9% (CVMP/627/01)
Doxybactin, a second generation Tetracycline, can be used to target conditions caused by bacteria sensitive to doxycycline such as rhinitis, bronchopneumonia, and interstitial nephritis in dogs and respiratory infections in cats. It will be available in multiple tablet strengths of 50 mg, 200 mg and 400 mg.
Spizobactin (spiramycin and metronidazole) is indicated for the treatment of (peri)oral and periodontal multi-bacterial infections in dogs such as those associated with gingivitis, stomatitis, glossitis, periodontitis, tonsillitis, dental fistula and other fistulous wounds in the oral cavity. It will be available in three different tablet strengths.
Both treatments are meat flavoured and the tablets can be divided twice for accurate dosing. This, Dechra says, is to help avoid the development of antibiotic resistance associated with under dosing.
Dechra Brand Manager Carol Morgan said: "The launch of Spizobactin and Doxybactin to the UK and ROI markets will offer vets even more choice when it comes to the targeted and responsible use of antibiotics for these specific conditions.
The proposal seems to have its roots in the First Rate Regulator initiative announced by Nick Stace in November 2012. As part of the initiative, the College commissioned Sally Williams and Associates to conduct research amongst stakeholders and report back with recommendations for being a first rate regulator.
One of those recommendations was to move to the civil standard of proof (page 33/34 here). There is no stated rationale for this recommendation, other than: "The majority of other professional regulators have moved to the civil standard of proof".
Nevertheless, the recommendation then found its way into the RCVS 2017-2019 Strategic Plan.
The proposal was then mentioned in the published summary of the Legislation Working Party's meeting in December 2017:
"In considering reform to the disciplinary process, the Registrar noted that the RCVS is one of the only regulators (and the only healthcare-based regulator) still using the criminal standard of proof (‘beyond all reasonable doubt’) when determining the facts of a case. Most other regulators used the civil standard of proof (‘on the balance of probabilities’) when making their determinations. Consideration of moving to the civil standard has also been carried over from the College’s previous Strategic Plan and the Registrar agreed to review the last six months’ cases to assess what the likely outcome of those cases would have been under the civil standard, and the cost of change. The Working Party also decided to contact other regulators about their disciplinary processes, in order to gather information about their experiences of what does and does not work, both for long-standing issues and new reforms."
The proposal then resurfaced last week in the Veterinary Record, which reported that the College is in 'advanced discussions' about adopting the lower standard (Standard of Proof for disciplinaries could change).
The College has now issued a statement to VetSurgeon.org as follows:
"The Royal College of Veterinary Surgeons (RCVS) is currently very much in the minority of regulators still using the criminal standard of proof ('beyond all reasonable doubt') in its disciplinary proceedings, rather than the civil standard of proof ('on the balance of probabilities').
"By comparison, all nine of the healthcare regulators in the human field (as overseen by the Professional Standards Authority) have moved to the civil standard, as have other regulators such as the Bar Standards Board and the Solicitors Regulation Authority.
"In our last two strategic plans we have committed to considering whether or not the RCVS should change the standard of proof in line with other regulators and these discussions have been taking place as part of the ongoing deliberations around legislative reform.
"A change to the standard of proof would require an amendment of our 2004 Procedure and Evidence Rules via the Privy Council rather than new primary legislation, but we would consult with the profession before any such changes were made and, at present, this matter has not been put before RCVS Council for a decision."
COMMENT
So, as it stands now, no evidence has yet been presented to the profession which supports the need for - or benefits of - a change to the standard of proof required in disciplinaries. The idea that it should be done simply because 'that's what the other regulators are doing' does not hold water. The veterinary profession is unique. According to the College's own research, it enjoys a remarkably high level of trust amongst the public. But at the same time, it also suffers one of the highest suicide rates.
Clearly Council will need to reflect extremely carefully on whether the members of such a widely trusted profession should face an even greater threat of losing their career, particularly when they seem to be at such a risk of vexatious complaints, fear of a disciplinary is already so high, and the consequences of this change on mental health in the profession could be so profound.
It may even be true to say that lives could depend on this decision.
Canergy contains propentofylline, a xanthine derivative which, Virbac says, potentiates the action of adenosine, a molecule found in the body which has a wide range of physiological effects which can be beneficial in the management of various age-related degenerative disease in dogs and cats1.
In particular, Virbac says propentofylline improves peripheral and cerebral vascular blood circulation, and has bronchodilating actions. This helps to increase oxygen supply to organs and muscles, which can result in a positive effect on overall demeanour and energy levels in older dogs.
Canergy is a beef-flavoured tablet which features SmartTab divisible design.
Canergy Product Manager Claire Lewis said: "Growing old should not have to be a barrier to enjoying life, so we are delighted to be able to add Canergy to the Virbac portfolio."
For more information, contact Virbac ob 01359 243243, email: enquiries@virbac.co.uk or visit: www.virbac.co.uk
The procedure was performed on a 13-year-old Siberian Husky called Marigold, which was diagnosed with a malignant mammary tumour last year.
Unfortunately, despite £20,000 worth of radiotherapy, Marigold failed to respond to treatment, and the tumour spread.
Marigold’s owner, Mrs Norma Pophosherti from Derby said: “We couldn’t bear to part with Marigold, she’s one of the family, so when we heard about the groundbreaking work being done at the University of Bromsgrove Veterinary School, we had to give it a go."
Unfortunately there was no realistic prospect of a donor from a matching breed of dog.
Thankfully, though, a local man with a 4-year-old Labrador stepped forward to help.
Hit by the cost of living crisis, he’d been unable to afford to keep his dog and was about to have it put to sleep when he heard about the Phophosherti family’s search for a donor.
Although he wished to remain anonymous, he said: “It gives me great comfort to think that Buddy will be able to live on, and spare the Phophoshertis from the pain of losing their beloved Marigold”
Professor Flora Olip MRCVS led a team of 6 veterinary surgeons who undertook the 28 hour procedure, which is estimated to have cost over £100,000.
She said: “This was a very tricky procedure which probably only had a 30% chance of success.
"But I’m delighted to say that Marigold’s new body has taken well, and she can now look forward to perhaps a whole more year with Phophosherti family, albeit as less of a Siberian Husky, and more of what you might call a Huskador"
Flora added: “More importantly, this heralds the way for similar procedures in humans, which I think are probably just a few years away now.”
Photo: Marigold, now one-third Siberian Husky, two-thirds Labrador.
Conducted in partnership with Royal Canin and led by Professor Alex German, the Feline Healthy Ageing Clinic, located at the University’s Small Animal Practice, will undertake extensive examinations of cats over 7 years of age.
Lead researcher Nathalie Dowgray BVSc MRCVS MANZCVS, and Kelly Eyre RVN are now recruiting mature cats in Liverpool and the surrounding area to offer health screenings and assessments of musculoskeletal, cardiac and retinal health.
Nathalie, said: "We are inviting 300 cats to take part in the Cat Prospective Ageing and Welfare Study (CatPAWS), a 5-year study; the largest of its kind.
"Cats will visit the practice every six months and we’re recruiting as many cats aged 7 to 10 years of age as we can at this stage.
"We will carry out a number of diagnostics including retinal examination and photography, blood and urine sampling and orthopaedic – including gait analysis - and dental examinations.
"The valuable data we collect will enable us to analyse the effects of ageing in more detail than ever before, and on a far larger scale.
"We’re ultimately aiming to improve the quality of life for these patients and instead of simply accepting what some may consider an inevitable decline in function, collectively take strides toward healthy ageing.”
Findings will be shared with Royal Canin, which will be trying to determine the role of nutrition alongside the many other factors affecting ageing in cats.
For more information, email: catpaws@liverpool.ac.uk
Dechra Veterinary Products has announced the reintroduction of Gelofusine®, a collodial plasma volume substitute used in the management of hypovolaemic shock in cats, dogs and horses. The company says that Gelofusine has the added advantage of containing no calcium and is therefore compatible with blood and blood products. Gelofusine is isooncotic (same colloid oncotic pressure) with plasma and therefore volume replacement is equivalent to the volume infused. Thus there is no danger of volume overload, as exists when using a plasma expander. Each bottle comes with a Free Dual Giving Set (worth £3.35), featuring a dual sectional dial with a 10%-40% scale for colloids.
According to the Animal Protection Agency, the rule had been included in the draft version of the new Animal Welfare (Licensing of Activities Involving Animals) Regulations 2018, which had been compiled with input from a number of stakeholders who agreed, based on scientific evidence, that snakes should be kept in enclosures at least as long as their body length.
However, the APA says that the rule was removed by Defra just days before publication, on the basis of one protest from a veterinary clinic closely associated with the pet trade and following what the APA describes as 'somewhat pally' correspondence between Defra officials and the representative of the veterinary clinic that had protested.
As a result, the ad-hoc group of biologists and vets, including Dr Phillip Arena (a biologist from Murdoch University), Rachel Grant (herpetologist from Northampton University), Angelo Lambiris (herpetologist), Catrina Steedman (reptile biologist), Clifford Warwick (reptile biologist) and veterinary surgeons Martin Whitehead MRCVS, Fredric Frye DVM, Mike Jessop MRCVS and Anthony Pilny DVM, have written to Defra, arguing that the scientific evidence significantly contradicts the veterinary clinic's protest, and that for their health and welfare snakes need to be provided with enclosures at least as long as they are.
Elaine Toland, biologist and Director of the APA, says this latest skirmish is symptomatic of a wider malaise: that whenever the APA meets with government officials, it finds itself up against a small group of pro-trade veterinary surgeons that tries to block any attempt to advance welfare for captive reptiles if it compromises the profitability of the trade.
Elaine said: "It's very frustrating, because the views of the vocal minority of pro-trade vets seem to us to be completely unrepresentative of exotic vets in general, who we've always found to be very supportive of our work and deeply frustrated by the welfare issues surrounding reptiles.
Ross Allan (pictured right), an RCVS Advanced Practitioner in Small Animal Surgery at Roundhouse, said: "It is well recognised that French Bulldogs have breed-related problems, specifically Brachycephalic Obstructive Airway Syndrome (BOAS), yet they remain one of the most popular dog breeds of the moment.
"Through the work we do with French Bulldog charities and the large number of BOAS procedures we undertake, we encounter many of this breed and recognise the frequency and challenges in diagnosing lateral condylar fractures in French Bulldogs.
"We are keen to highlight the ‘red-flags’ for vets faced with French Bulldog forelimb lameness, and hope these will assist vets in diagnosing these common fractures:
Age: most lateral humeral condylar fractures occur between 3-4 months of age.
Trauma: in 90% of cases the trauma is minor; a fall from the arms, or tumble off the bed.
Non-weight bearing: a French Bulldog presents with a non-weight bearing lameness X-rays are required even if no fractures are obvious on palpation.
Physical: feel for the medial and lateral epicondyles of the humerus. If they are not in line with each other there will be a fracture (in LHCFs the lateral condyle will generally move proximally).
X-rays: perfect positioning for X-rays is essential to pick up these fractures. Slight rotation can ‘hide’ small, or incomplete fractures.
"We urge vets to be mindful of LCHFs when presented with a French Bulldog with a forelimb lameness and recommend that they add this condition to their differential list. Swift diagnosis greatly simplifies the surgery required and improves the likelihood of a successful outcome.
"French Bulldogs are well-muscled, stoical dogs, so these fractures are often problematic to detect on clinical examination. The key point when undertaking a medical examination of French Bulldogs is that vets feel for the medial and lateral epicondyles of the humerus to assess if they are in perfect alignment: if one is higher than the other, this suggests a fracture; even if a fracture is not readily visible on X-ray.
"And great care must be taken to ensure that X-rays are positioned perfectly because if the elbow is rotated – even slightly – these fractures can easily be overlooked. They are good at hiding!"
Roundhouse Referrals says it has recently treated several French Bulldogs with lateral humeral condylar fractures deploying various surgical techniques: usually a transcondylar lag screw along with a supracondylar K-wire, or additional supracondylar positional screw or plate.
To make an enquiry or refer a patient contact Roundhouse Referrals at 0141 649 1316 www.rhr.vet
Linnaeus was founded in 2014 from Willows Veterinary Centre and Referral Service and a team of 120. It was acquired in 2018 by Mars Veterinary Health and has continued to grow, now employing around 3,500 staff.
The referral practices joining Linnaeus are Anderson Moores near Winchester, Dick White Referrals near Cambridge, North West Veterinary Referrals and Eye Vet in Runcorn and Veterinary Specialists Scotland in Livingston.
Linnaeus says the practices will retain their existing branding and will initially continue with business as usual, with all staff transferring to Linnaeus after completion.
Bart Johnson, CEO of Linnaeus, said: “We are delighted to welcome our new colleagues and these fantastic and highly-respected referral practices into the Linnaeus family and to grow our offering further, taking another step towards making an even better world for pets.”
Alejandro Bernal, President, Mars Veterinary Health International, part of Mars Petcare which owns Linnaeus, said: “Pet care has been an important part of Mars for over 80 years and this strategic acquisition reaffirms our commitment both to the pet care industry and veterinary profession.
For more information, visit www.linnaeusgroup.co.uk.
Boehringer Ingelheim has launched a cat-specific presentation of Metacam Injection combined with a new indication which permits the company's existing oral suspension (0.5mg/ml meloxicam) to be used for up to four follow-on days.
The company says this will give veterinary surgeons increased flexibility for managing feline post-operative pain, and that the new Metacam 2mg/ml Injection helps accurate dosing. Used at the recommended dose rate of 0.2mg/kg, the injection can be followed by Metacam 0.5mg/ml Oral Suspension to provide up to five days of analgesia following surgical procedures in cats. The licensed claims for Metacam 5mg/ml Injection for dogs and cats have not changed.
Boehringer added that Metacam is now the only brand which enables vets to offer their feline patients several days of post-operative analgesia, as well as being approved for long-term use for chronic musculoskeletal disease.
Claire Fowler, Boehringer Ingelheim's companion animal marketing manager, says that the new presentation and indication are significant developments in feline post-operative pain management: "Around half of all dogs undergoing surgery receive an injectable NSAID followed by a follow-on oral NSAID. In cats this figure is around 22%, yet there is no evidence to suggest that pain perception in cats should be any different to that of dogs".